Deep Relief (Gel) Instructions for Use
Marketing Authorization Holder
Mentholatum Company, Ltd. (United Kingdom)
Contact Information
DELTA MEDICAL LLC (Russia)
ATC Code
M02AA (Topical non-steroidal anti-inflammatory drugs)
Active Substances
Ibuprofen (Rec.INN registered by WHO)
Levomenthol (Rec.INN registered by WHO)
Dosage Form
| Deep Relief | External use gel 50 mg+30 mg/1 g: tubes 15 g, 50 g, or 100 g |
Dosage Form, Packaging, and Composition
Gel for external use transparent, with a menthol odor.
| 1 g | |
| Ibuprofen | 50 mg |
| Levomenthol | 30 mg |
Excipients: purified water, denatured ethanol 96%, propylene glycol, diisopropanolamine, carbomer.
15 g – aluminum tubes (1) – cardboard boxes.
30 g – aluminum tubes (1) – cardboard boxes.
50 g – aluminum tubes (1) – cardboard boxes.
100 g – aluminum tubes (1) – cardboard boxes.
Clinical-Pharmacological Group
NSAIDs for external use
Pharmacotherapeutic Group
NSAID
Pharmacological Action
A combined preparation for external use, containing Ibuprofen and Levomenthol.
Ibuprofen is an NSAID; when applied externally, it has an analgesic, anti-inflammatory, and anti-exudative effect in the symptomatic treatment of joints, tendons, ligaments, and muscles.
Levomenthol (menthol) has a local irritant effect, which causes the development of the drug’s rapid analgesic effect.
Deep Relief reduces pain and inflammation, is effective for joint pain during movement and at rest, and reduces morning joint stiffness.
Indications
- Diseases of the musculoskeletal system (including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteochondrosis with radicular syndrome, radiculitis, lumbago, sciatica);
- Rheumatic diseases of soft tissues (including tenosynovitis, bursitis, damage to periarticular tissues);
- Post-traumatic inflammation of soft tissues and joints (including due to sprains, strains, and bruises);
- Back pain, lower back pain.
ICD codes
| ICD-10 code | Indication |
| M05 | Seropositive rheumatoid arthritis |
| M15 | Polyosteoarthritis |
| M19.9 | Unspecified arthrosis |
| M42 | Spinal osteochondrosis |
| M45 | Ankylosing spondylitis |
| M47 | Spondylosis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M54.9 | Dorsalgia, unspecified |
| M65 | Synovitis and tenosynovitis |
| M70 | Soft tissue disorders related to use, overuse, and pressure |
| M71 | Other bursopathies |
| M75.0 | Adhesive capsulitis of shoulder |
| M79.0 | Unspecified rheumatism |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.3 | Dislocation, sprain and strain of joint and ligament of unspecified body region |
| ICD-11 code | Indication |
| 8B93.Z | Radiculopathy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA27.2 | Palindromic rheumatism |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA8Z | Degenerative disease of spine, unspecified |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB40.Z | Tenosynovitis, unspecified |
| FB50.1 | Bursitis associated with use, overuse or pressure |
| FB50.Z | Bursitis, unspecified |
| FB51.3 | Fibroblastic rheumatism |
| FB53.0 | Adhesive capsulitis of shoulder |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| ME84.Z | Back pain, unspecified |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.3 | Dislocation, sprain or strain of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The preparation is applied externally.
For adults and children over 14 years of age, a small amount of gel (3-5 cm) is applied up to 4 times/day in a thin layer to the skin over the inflammation site and gently rubbed in.
After using Deep Relief, hands should be washed if they are not the area being treated.
The duration of use of the preparation without consulting a doctor is no more than 10 days.
Adverse Reactions
Allergic reactions generalized skin rash, urticaria, angioneurotic edema, bronchospastic reactions, photosensitivity, eczema, contact dermatitis (including itching, redness, swelling of the treated skin area, papules, vesicles, peeling).
Contraindications
- Bronchial asthma provoked by taking acetylsalicylic acid or other NSAIDs;
- Impaired skin integrity;
- Pregnancy;
- Lactation period (breastfeeding);
- Children under 14 years of age;
- Hypersensitivity to ibuprofen or other components of the preparation.
Use with caution in exacerbation of hepatic porphyria, erosive and ulcerative lesions of the gastrointestinal tract, severe impairment of liver and kidney function, chronic heart failure, bronchial asthma, in elderly patients.
Use in Pregnancy and Lactation
The use of the preparation is contraindicated during pregnancy and lactation (breastfeeding).
Use in Hepatic Impairment
Use the preparation with caution in exacerbation of hepatic porphyria, severe impairment of liver function.
Use in Renal Impairment
Use the preparation with caution in severe impairment of kidney function.
Pediatric Use
Deep Relief should not be used in children under 14 years of age without a corresponding doctor’s recommendation.
Geriatric Use
Use the preparation with caution in elderly patients.
Special Precautions
Patients with kidney diseases should consult a doctor before using the preparation.
The gel should be applied to intact skin, avoiding contact with eyes, mucous membranes, and open wound surfaces. After application, an occlusive (airtight) bandage should not be applied.
With long-term use of the preparation in large doses, there is a risk of developing side effects.
Use in pediatrics
Deep Relief should not be used in children under 14 years of age without a corresponding doctor’s recommendation.
Overdose
Cases of overdose have not been described.
Drug Interactions
Deep Relief may enhance the effect of drugs causing photosensitivity.
Clinically significant interaction with other medicinal products has not been described.
Storage Conditions
The preparation should be stored out of the reach of children at a temperature not exceeding 25°C (77°F).
Shelf Life
The shelf life is 3 years.
Dispensing Status
The preparation is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer